Skip to main
ILMN
ILMN logo

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 42 analyst ratings
Buy
Strong Buy 26%
Buy 26%
Hold 36%
Sell 10%
Strong Sell 2%

Bulls say

Illumina has historically demonstrated a strong ability to increase revenue by leveraging demand elasticity, where the incremental demand for sequencing outweighs pricing declines, suggesting robust market dynamics. The company aims for high single-digit revenue growth by 2027, supported by its innovative multiomic technologies and a solid product roadmap, which indicates a proactive approach to enhancing market presence. Additionally, despite challenges in the Chinese market, Illumina is projected to achieve approximately 14% EPS growth in 2026, illustrating underlying financial strength and resilience in its operational performance.

Bears say

Illumina has lowered its 2025 guidance for non-GAAP diluted EPS to $4.50, reflecting reduced earnings contributions from China and current macroeconomic challenges, signaling potential ongoing revenue headwinds. The company's stock has declined approximately 40% since solid Q4'24 results due to fears over possible operational constraints in China, which represents about 7% of its sales, and concerns about competitive pressures and NIH funding cuts. Furthermore, if Illumina cannot achieve revenue or earnings growth comparable to its life science tools peers, it may face continued trading at a relative discount, further complicating its financial outlook.

Illumina (ILMN) has been analyzed by 42 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 26% recommend Buy, 36% suggest Holding, 10% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 42 analysts, Illumina (ILMN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.